Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A dose-escalation and dose expansion Phase I clinical study of HQP1351 in patients with Chronic myeloid leukaemia (CML)

Trial Profile

A dose-escalation and dose expansion Phase I clinical study of HQP1351 in patients with Chronic myeloid leukaemia (CML)

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs HQP 1351 (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Dec 2018 Preliminary results assessing safety and efficacy of HQP1351 in patients with chronic myeloid leukemia, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 03 Dec 2018 According to an Ascentage Pharma media release, data from this study were presented at the 60th American Society of Hematology Annual Meeting.
    • 03 Dec 2018 Results presented in an Ascentage Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top